BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:laroprovstat/rosuvastatin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of laroprovstat/rosuvastatin\, from Clinical
 Trials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07619118-8630@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07619118)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With 
 Hypercholesterolaemia\nEstimated primary completion: 28 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0761911
 8
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619131-8630@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07619131)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Laroprovstat\, Rosuvastatin and Placebo
  on LDL-C in LLT-naïve Patients.\nEstimated primary completion: 30 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat-ros
 uvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07619131
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930507-8630@assetmemo.bio
DTSTAMP:20261121T005015Z
DTSTART;VALUE=DATE:20271011
DTEND;VALUE=DATE:20271012
SUMMARY:laroprovstat/rosuvastatin: Phase 3 readout est. (NCT07930507)
DESCRIPTION:laroprovstat/rosuvastatin\, phase 3\, Atherosclerotic Cardiovas
 cular Disease.\nStudy: A Phase III Study to Assess the Effect of FDC Larop
 rovstat/Rosuvastatin Compared With Laroprovstat\, Rosuvastatin\, and Place
 bo on LDL-C in LLT-naïve Patients\nEstimated primary completion: 11 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/laroprovstat
 -rosuvastatin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07930507
URL:https://assetmemo.bio/drug/laroprovstat-rosuvastatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
